Publikationen, an denen er mitarbeitet CARLOS JAVIER ANGUITA VELASCO (27)

2024

  1. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

    Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12

  2. Identification of predictive models including polymorphisms in cytokines genes and clinical variables associated with post-transplant complications after identical HLA-allogeneic stem cell transplantation

    Frontiers in Immunology, Vol. 15

2023

  1. Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide

    Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567

2022

  1. Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy

    Transfusion, Vol. 62, Núm. 10, pp. 2143-2147

  2. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation

    Frontiers in immunology, Vol. 13, pp. 1002959

  3. FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 16

2021

  1. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  2. Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 12

  3. Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 62, Núm. 5, pp. 1178-1186

  4. Next generation cytogenetics in myeloid hematological neoplasms: Detection of cnvs and translocations

    Cancers, Vol. 13, Núm. 12

  5. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

    Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553

2019

  1. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders

    AIDS, Vol. 33, Núm. 9, pp. 1441-1447

  2. Next-generation sequencing improves diagnosis, prognosis and clinical management of myeloid neoplasms

    Cancers, Vol. 11, Núm. 9

  3. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation

    Blood Advances, Vol. 3, Núm. 21, pp. 3351-3359

  4. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide

    Frontiers in Immunology, Vol. 10

  5. Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation

    Chemotherapy, Vol. 64, Núm. 2, pp. 57-61

2017

  1. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

    Bone Marrow Transplantation, Vol. 52, Núm. 8, pp. 1138-1143

  2. Transient hemolysis due to anti-D and anti-A1 produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation

    Transfusion, Vol. 57, Núm. 10, pp. 2355-2358

2016

  1. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 483-491

2015

  1. Achievement of early complete donor chimerism in CD25+-activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation

    Experimental Hematology, Vol. 43, Núm. 1, pp. 4-13